Fusion Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Fusion Pharmaceuticals

08/11/2022 14:32

* Fusion Pharmaceuticals Inc  FUSN.OQ  reported a quarterly
adjusted loss of 55 cents​​ per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for a loss of 50 cents per share.
    * Revenue fell 48.9% to $166.00 thousand from a year ago;
analysts
expected $100.00 thousand. 
    * Fusion Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 55 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Fusion Pharmaceuticals Inc shares had fallen by 34.2% this
quarter and lost 52.5% so far this year.
    * The company reported a quarterly loss of $24.01 million.
    * Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $13.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 02:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.50          -0.55          Missed
 Jun. 30 2022      -0.53          -0.44          Beat
 Mar. 31 2022      -0.48          -0.46          Beat
 Dec. 31 2021      -0.47          -0.40          Beat